NHSA’s 2022 Healthcare Security Report Reveals Break-Even Performance
The National Healthcare Security Administration (NHSA) has released its annual “Healthcare Security Development Statistical Bulletin”...
Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...
Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma
Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...
HealiRNA Secures RMB 100 Million in Pre-Series A Funding for Nucleic Acid Drug Development
China-based nucleic acid drug specialist Suzhou HealiRNA has reportedly raised over RMB 100 million (USD...
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...
Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Autoimmune Therapies
China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million)...
Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development
Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions”...
Haihe Pharma’s Glumetinib Gains Conditional NMPA Approval for NSCLC
Shanghai Haihe Pharmaceutical Co., Ltd’s Category 1 product, glumetinib, has received conditional market approval from...
AmVision Biotech Secures Nearly $14.34M in Series A+ for Ophthalmology Innovations
AmVision Biotech, a leading ophthalmology device platform company based in Guangzhou, has reportedly secured close...
JW Therapeutics Launches Carteyva Clinical Study for High-Risk Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
Chongqing Evaheart Secures Near $100M in Series A for Heart Failure Platform
Chongqing Evaheart Medical Device Co., Ltd has reportedly secured close to USD 100 million in...
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...
Haihe Pharma’s Glumetinib Receives Conditional Approval for NSCLC Treatment
Shanghai Haihe Pharmaceutical Co., Ltd’s Category 1 product, glumetinib, has obtained conditional market approval from...
AmVision Biotech Secures RMB 100 Million in Series A+ Financing for Ophthalmology Innovation
AmVision Biotech, an ophthalmology device platform company based in Guangzhou, has reportedly raised close to...
JW Therapeutics Initiates Clinical Study for Carteyva in First-Line High-Risk Large B-Cell Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
Evaheart Med Raises USD 100 Million in Series A Funding Led by Sinovac
Chongqing Evaheart Medical Device Co., Ltd has reportedly raised close to USD 100 million in...
HQ Pharma and Shanxi HCXF Partner to Expand Oral Soluble Film R&D and Production
China-based firms HQ Pharma and Shanxi HCXF Pharmaceutical Co., Ltd have agreed to jointly expand...
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...
Sumitomo Pharma Secures Rights to Vibegron for Asian Markets
Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical...
Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...